Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

612.14 +0.66 (+0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 717,782
Open 613.11
Bid (Size) 610.00 (40)
Ask (Size) 615.95 (40)
Prev. Close 611.48
Today's Range 605.01 - 616.54
52wk Range 503.25 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
REGN (NASDAQ:REGN) Presents a Classic Value Opportunity with Strong Fundamentals ↗
Via Chartmill
News headline image
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Performance

YTD
-21.1%
-21.1%
1 Month
-15.4%
-15.4%
3 Month
-18.0%
-18.0%
6 Month
-18.0%
-18.0%
1 Year
+18.0%
+18.0%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
Top S&P500 movers in Monday's session ↗
Via Chartmill
Unusual volume S&P500 stocks in Monday's session ↗
Via Chartmill
News headline image
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
Via StockStory
News headline image
2 S&P 500 Stocks with Solid Fundamentals and 1 We Find Risky
Via StockStory
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Nasdaq 100 Stocks We Find Risky
Via StockStory
News headline image
Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN): Grabar Law Office is Investigating Claims on Your
From Grabar Law Office
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Important Notice to Long-Term Shareholders of Molina Healthcare, Inc. (NYSE: MOH); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Grabar Law Office is Investigating Claims on
From Grabar Law Office
Via GlobeNewswire
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Via MarketBeat
News headline image
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron
Via StockStory
Topics Artificial Intelligence
News headline image
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 of Wall Street’s Favorite Stock with Solid Fundamentals and 2 We Question
Via StockStory
Topics Supply Chain
News headline image
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Why Regeneron (REGN) Shares Are Trading Lower Today
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 612.14
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 06/12/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 56.18B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 56B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.